Clinical data | |
---|---|
Trade names | Deracyn |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Metabolites | N-desmethyladinazolam
N, N-didesmethyladinazolam estazolam alpha-hydroxy-alprazolam |
Elimination half-life | < 3 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H18ClN5 |
Molar mass | 351.84 g·mol−1 |
3D model (JSmol) | |
Melting point | 171–172.5 °C (339.8–342.5 °F) |
Solubility in water | LogP: 4.16
Soluble in dichloromethane and methanol Salt (mesylate) soluble in water mg/mL (20 °C) |
| |
| |
(verify) |
Adinazolam[1] (marketed under the brand name Deracyn) is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It possesses anxiolytic,[2] anticonvulsant, sedative, and antidepressant[3][4] properties. Adinazolam was developed by Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[5] Adinazolam was never FDA approved and never made available to the public market; however, it has been sold as a designer drug.[6]